alanine has been researched along with Hepatitis C in 18 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Envelope glycoprotein 2 (E2) of hepatitis C virus contains 18 conserved cysteine (Cys) residues in its ectodomain." | 7.80 | Alanine scanning mutagenesis of hepatitis C virus E2 cysteine residues: Insights into E2 biogenesis and antigenicity. ( Guan, M; Liu, X; Liu, Y; Peng, H; Qi, Z; Ren, H; Tang, Z; Wang, W; Wu, D; Xu, Q; Zhao, P; Zhu, Y, 2014) |
| "Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 5.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
| " Upon transfection, the replicon RNA replicated in various cell lines, and was sensitive to interferon alpha (IFN-α), remdesivir, but was resistant to hepatitis C virus inhibitors daclatasvir and sofosbuvir." | 4.02 | A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2. ( Chen, S; Song, W; Yi, Z; Yuan, Z; Zhang, Y, 2021) |
| " After examining the molecular structures and activities of hepatitis C viral inhibitors and comparing hepatitis C virus and coronavirus replication, we previously postulated that the FDA-approved hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) might inhibit SARS-CoV-2." | 3.96 | Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. ( Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C, 2020) |
| "Envelope glycoprotein 2 (E2) of hepatitis C virus contains 18 conserved cysteine (Cys) residues in its ectodomain." | 3.80 | Alanine scanning mutagenesis of hepatitis C virus E2 cysteine residues: Insights into E2 biogenesis and antigenicity. ( Guan, M; Liu, X; Liu, Y; Peng, H; Qi, Z; Ren, H; Tang, Z; Wang, W; Wu, D; Xu, Q; Zhao, P; Zhu, Y, 2014) |
| "AL-335 was well tolerated when administered as single and multiple doses, with an acceptable pharmacokinetic profile." | 2.87 | Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. ( Astruc, B; Beigelman, L; Berliba, E; Blatt, LM; Chanda, S; Fry, J; Kakuda, TN; Khorlin, N; McClure, MW; Patat, A; Streinu-Cercel, A; Tsertsvadze, T; Vijgen, L; Vuong, J; Westland, C; Zhang, Q, 2018) |
| "Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 1.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 8 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Pfaff-Kilgore, JM | 1 |
| Davidson, E | 1 |
| Kadash-Edmondson, K | 1 |
| Hernandez, M | 1 |
| Rosenberg, E | 1 |
| Chambers, R | 1 |
| Castelli, M | 1 |
| Clementi, N | 1 |
| Mancini, N | 1 |
| Bailey, JR | 1 |
| Crowe, JE | 1 |
| Law, M | 1 |
| Doranz, BJ | 1 |
| Nguyenla, X | 1 |
| Wehri, E | 1 |
| Van Dis, E | 1 |
| Biering, SB | 1 |
| Yamashiro, LH | 1 |
| Zhu, C | 1 |
| Stroumza, J | 1 |
| Dugast-Darzacq, C | 1 |
| Graham, TGW | 1 |
| Wang, X | 1 |
| Jockusch, S | 2 |
| Tao, C | 2 |
| Chien, M | 2 |
| Xie, W | 1 |
| Patel, DJ | 1 |
| Meyer, C | 1 |
| Garzia, A | 1 |
| Tuschl, T | 1 |
| Russo, JJ | 2 |
| Ju, J | 2 |
| Näär, AM | 1 |
| Stanley, S | 1 |
| Schaletzky, J | 1 |
| Goonawardane, N | 1 |
| Yin, C | 1 |
| Harris, M | 1 |
| Huhn, GD | 1 |
| Ramgopal, M | 1 |
| Jain, MK | 1 |
| Hinestrosa, F | 1 |
| Asmuth, DM | 1 |
| Slim, J | 1 |
| Goldstein, D | 1 |
| Applin, S | 1 |
| Ryu, JH | 1 |
| Jiang, S | 1 |
| Cox, S | 1 |
| Das, M | 1 |
| Nguyen-Cleary, T | 1 |
| Piontkowsky, D | 1 |
| Guyer, B | 1 |
| Rossaro, L | 1 |
| Haubrich, RH | 1 |
| Li, G | 1 |
| De Clercq, E | 1 |
| Li, X | 1 |
| Kumar, S | 1 |
| Morozova, I | 1 |
| Kalachikov, S | 1 |
| Zhang, Y | 1 |
| Song, W | 1 |
| Chen, S | 1 |
| Yuan, Z | 1 |
| Yi, Z | 1 |
| Gammeltoft, KA | 1 |
| Zhou, Y | 1 |
| Duarte Hernandez, CR | 1 |
| Galli, A | 1 |
| Offersgaard, A | 1 |
| Costa, R | 1 |
| Pham, LV | 1 |
| Fahnøe, U | 1 |
| Feng, S | 1 |
| Scheel, TKH | 1 |
| Ramirez, S | 1 |
| Bukh, J | 1 |
| Gottwein, JM | 1 |
| Feng, JY | 1 |
| Wang, T | 1 |
| Park, Y | 1 |
| Babusis, D | 1 |
| Birkus, G | 1 |
| Xu, Y | 1 |
| Voitenleitner, C | 1 |
| Fenaux, M | 1 |
| Yang, H | 1 |
| Eng, S | 1 |
| Tirunagari, N | 1 |
| Kirschberg, T | 1 |
| Cho, A | 1 |
| Ray, AS | 1 |
| Alsunaid, SR | 1 |
| Ashraf, H | 1 |
| Soubani, AO | 1 |
| McClure, MW | 1 |
| Berliba, E | 1 |
| Tsertsvadze, T | 1 |
| Streinu-Cercel, A | 1 |
| Vijgen, L | 1 |
| Astruc, B | 1 |
| Patat, A | 1 |
| Westland, C | 1 |
| Chanda, S | 1 |
| Zhang, Q | 2 |
| Kakuda, TN | 1 |
| Vuong, J | 1 |
| Khorlin, N | 1 |
| Beigelman, L | 2 |
| Blatt, LM | 1 |
| Fry, J | 1 |
| Wang, G | 1 |
| Dyatkina, N | 1 |
| Prhavc, M | 1 |
| Williams, C | 1 |
| Serebryany, V | 1 |
| Hu, Y | 1 |
| Huang, Y | 1 |
| Wan, J | 1 |
| Wu, X | 1 |
| Deval, J | 1 |
| Fung, A | 1 |
| Jin, Z | 1 |
| Tan, H | 1 |
| Shaw, K | 1 |
| Kang, H | 1 |
| Tam, Y | 1 |
| Stoycheva, A | 1 |
| Jekle, A | 1 |
| Smith, DB | 1 |
| Wang, W | 1 |
| Guan, M | 1 |
| Liu, Y | 1 |
| Xu, Q | 1 |
| Peng, H | 1 |
| Liu, X | 1 |
| Tang, Z | 1 |
| Zhu, Y | 1 |
| Wu, D | 1 |
| Ren, H | 1 |
| Zhao, P | 1 |
| Qi, Z | 1 |
| García-Broncano, P | 1 |
| Berenguer, J | 1 |
| Fernández-Rodríguez, A | 1 |
| Pineda-Tenor, D | 1 |
| Jiménez-Sousa, MÁ | 1 |
| García-Alvarez, M | 1 |
| Miralles, P | 1 |
| Aldámiz-Echevarria, T | 1 |
| López, JC | 1 |
| Micheloud, D | 1 |
| Resino, S | 1 |
| Otoguro, T | 1 |
| Tanaka, T | 1 |
| Kasai, H | 1 |
| Yamashita, A | 1 |
| Moriishi, K | 1 |
| Noguchi, T | 1 |
| Tamori, A | 1 |
| Ogura, N | 1 |
| Hori, Y | 1 |
| Ikeda, S | 1 |
| Nishiguchi, S | 1 |
| Ezzikouri, S | 1 |
| El Feydi, AE | 1 |
| Chafik, A | 1 |
| Afifi, R | 1 |
| El Kihal, L | 1 |
| Benazzouz, M | 1 |
| Hassar, M | 1 |
| Pineau, P | 1 |
| Benjelloun, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid[NCT02707601] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-01 | Completed | ||
| Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist[NCT04594356] | 120 participants (Actual) | Observational | 2020-11-19 | Completed | |||
| Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection[NCT04326036] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2020-03-25 | Enrolling by invitation | ||
| A Randomized, Double-blind, Placebo-controlled, First-in-human, 3 Part Study of Orally Administered AL-335 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending [NCT02339207] | Phase 1 | 112 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02707601)
Timeframe: Up to 32 weeks plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 62.5 |
| F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 69.4 |
| E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12) | 83.8 |
| F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12) | 79.7 |
Sustained Virologic Response (SVR12) was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 98.6 |
| F/R/TAF + LDV/SOF | 95.8 |
SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 98.6 |
| F/R/TAF + LDV/SOF | 98.6 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02707601)
Timeframe: 24 weeks after start of HIV treatment
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 1.4 |
| F/R/TAF + LDV/SOF | 1.4 |
2 trials available for alanine and Hepatitis C
| Article | Year |
|---|---|
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Vira | 2020 |
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
Topics: Adult; Alanine; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gen | 2018 |
16 other studies available for alanine and Hepatitis C
| Article | Year |
|---|---|
Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening.
Topics: Alanine; Antibodies, Monoclonal; Hepacivirus; Hepatitis C; Humans; Viral Envelope Proteins; Virus In | 2022 |
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Hepacivirus; Hepatitis | 2022 |
Phenotypic analysis of mutations at residue 146 provides insights into the relationship between NS5A hyperphosphorylation and hepatitis C virus genome replication.
Topics: Alanine; Amino Acid Substitution; Cell Line, Tumor; Genome, Viral; Genotype; Hepacivirus; Hepatitis | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Coronav | 2020 |
A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Chromo | 2021 |
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19 Drug Tre | 2021 |
Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment.
Topics: Adenosine; Administration, Oral; Alanine; Animals; Antiviral Agents; Caco-2 Cells; Cells, Cultured; | 2018 |
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell T | 2018 |
Public health round-up.
Topics: Adenosine Monophosphate; Alanine; Aminoisobutyric Acids; Anti-Bacterial Agents; Antibodies, Monoclon | 2019 |
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
Topics: Alanine; Animals; Antiviral Agents; Cell Line, Tumor; Dogs; Hepacivirus; Hepatitis C; Humans; Nuclei | 2019 |
Alanine scanning mutagenesis of hepatitis C virus E2 cysteine residues: Insights into E2 biogenesis and antigenicity.
Topics: Alanine; Amino Acid Substitution; Antibodies, Viral; Cysteine; Hepacivirus; Hepatitis C; Humans; Mut | 2014 |
PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study.
Topics: Adult; Alanine; Amino Acid Substitution; Cardiovascular Diseases; Coinfection; Cross-Sectional Studi | 2014 |
Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity.
Topics: Alanine; Antiviral Agents; Azepines; Carbamates; Cell Line; Cell Survival; Cells, Cultured; Drug Syn | 2016 |
Investigation of interferon-α response by a single amino acid substitution of nonstructural protein 5A in hepatitis C virus-infected patients.
Topics: Adult; Aged; Alanine; Alanine Transaminase; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Vi | 2011 |
Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients.
Topics: Aged; Alanine; Carcinoma, Hepatocellular; Female; Gene Frequency; Genetic Predisposition to Disease; | 2008 |